School of Medicine
Showing 1-10 of 34 Results
-
Zinaida Good, Ph.D.
Postdoctoral Scholar, Stanford Cancer Center
BioZinaida Good, Ph.D. is a 2020 Stanford Cancer Institute Fellow training with Profs. Crystal L. Mackall, M.D. and Sylvia K. Plevritis, Ph.D. at Stanford University. Dr. Good’s research is focused on investigating how chimeric antigen receptor (CAR)-expressing T lymphocytes succeed or fail in patients, in order to guide the design of the next generation of engineered cell therapies. Leveraging multimodal single-cell data analysis, tumor microenvironment imaging, and data integration, she aims to identify features of optimal CAR T cells from patient data. Her projects include: (1) identification of CAR T-cell populations that are associated with durable complete response in diffuse large B-cell lymphoma (DLBCL) patients receiving a CD19-targeted therapy Axicabtagene ciloleucel; (2) defining features of successful CAR T-cell clones in DLBCL patients receiving bispecific CD19/CD22-targeted CAR T cells on a Stanford trial; and (3) identifying modulation points to improve CAR T-cell function within the tumor microenvironment in DLBCL and solid tumors. Dr. Good earned her Ph.D. in Computational & Systems Immunology from Stanford University in April 2018, where she trained with Profs. Garry P. Nolan, Ph.D. and Sean C. Bendall, Ph.D. Her background is in immunology (B.S. and M.S. from the University of British Columbia in Vancouver, Canada) and oncology (she worked for 2 years in Discovery Oncology at Genentech). As a result of her academic training and work experiences, Dr. Good became an inventor on 2 patent applications, co-authored 7 papers, and wrote 3 first-author manuscripts (Good and Sarno et al. Nature Medicine, 2018; Good et al. Nature Biotechnology, 2019; Good et al. Trends in Immunology, 2019). Her long-term interest is in the systems-level events required for a coordinated immune attack against cancer.
-
Muhammad Murtaza Hassan
Postdoctoral Scholar, Stanford Cancer Center
BioMurtaza is a chemical biologist that joined the Gray Lab in July 2021 as a postdoctoral researcher. He developed his love for medicinal chemistry and chemical biology at the undergraduate level at the University of Toronto Mississauga which then motivated him to pursue an MSc (York University, Supervisor: Prof. Edward Lee-Ruff, 2017) and PhD (University of Toronto Mississauga, Supervisor: Patrick T. Gunning, 2021) in the field. His PhD work involved the development of some of the most potent and selective HDAC8 inhibitors known-to-date. It incorporated inhibitors with L-shaped conformational constraints to compliment the L-shaped HDAC8 pocket. His current work at the Gray Lab revolves around the development of first-in-class covalent inhibitors for recently discovered epigenetic targets that have been shown to synergize with anticancer immunotherapy. Additionally, he is interested in developing small-molecule chemoproteomic tools that can potentially expand our ability to target otherwise undruggable proteins, by using protein-protein interactions for cross-labelling/drugging interacting proteins.
